- Home
- CSIQ vs PHAR Comparison
CSIQ vs PHAR Comparison
Compare CSIQ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSIQ | PHAR |
|---|---|---|
| Founded | 2001 | 1988 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CSIQ | PHAR |
|---|---|---|
| Price | $14.27 | $15.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $18.33 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.9M | 18.1K |
| Earning Date | 03-19-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.53 | $10.04 |
| Revenue Next Year | $12.74 | $2.70 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.57 | $7.50 |
| 52 Week High | $34.59 | $21.34 |
Technical Indicators
Market Signals| Indicator | CSIQ | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 44.36 |
| Support Level | $13.48 | $14.88 |
| Resistance Level | $17.07 | $17.29 |
| Average True Range (ATR) | 0.88 | 0.67 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 15.65 | 29.79 |
Price Performance
Historical ComparisonAbout CSIQ Canadian Solar Inc. (ON)
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.